D. Flannery, S. Gouma, Miren B Dhudasia, S. Mukhopadhyay, M. R. Pfeifer, E. C. Woodford, J. Gerber, C. P. Arevalo, M. Bolton, M. Weirick, E. Goodwin, E. M. Anderson, A. Greenplate, Justin Kim, N. Han, A. Pattekar, J. Dougherty, O. Kuthuru, D. Mathew, A. Baxter, L. Vella, J. Weaver, A. Verma, R. Leite, Jeffrey S. Morris, D. Rader, M. Elovitz, E. Wherry, K. Puopolo, S. Hensley
Science Immunology, 2020
Limited data are available for pregnant women affected by SARS-CoV-2. Serological tests are critically important for determining SARS-CoV-2 exposures within both individuals and populations. We validated a SARS-CoV-2 spike receptor binding domain serological test using 834 pre-pandemic samples and 31 samples from COVID-19 recovered donors. We then completed SARS-CoV-2 serological testing of 1,293 parturient women at two centers in Philadelphia from April 4 to June 3, 2020. We found 80/1,293 (6.2%) of parturient women possessed IgG and/or IgM SARS-CoV-2-specific antibodies. We found race/ethnicity differences in seroprevalence rates, with higher rates in Black/non-Hispanic and Hispanic/Latino women. Of the 72 seropositive women who also received nasopharyngeal polymerase chain reaction testing during pregnancy, 46 (64%) were positive. Continued serologic surveillance among pregnant women may inform perinatal clinical practices and can potentially be used to estimate exposure to SARS-CoV-2 within the community. Over six percent of parturient women in Philadelphia (4 April–3 June 2020) had serological evidence of exposure to SARS-CoV-2.
Cited by 65 publications.
Field of study: Medicine